AGRICULTURE
Global CRISPR Gene Editing Market - Industry Trends and Forecast to 2032
REPORT OVERVIEW
Global CRISPR Gene Editing Market, By Type (CRISPR Products and CRISPR Services), Application (Agriculture, Biomedical, Industrial, Genome Engineering, Disease Models, Functional Genomics, and Others), End User (Academic Institutes and Research Centers, Biotechnology Companies, Contract Research Organizations (CROs), Pharmaceutical and Biopharmaceutical Companies, and Others), Region (North America, Europe, Asia-Pacific, South America, Middle East and Africa) – Industry Trends and Forecast to 2032.
Market Insights
Market Dynamics
- Rising prevalence of chronic diseases
- Surging public and private investments
- High costs associated with CRISPR therapies
- Ethical concerns and regulatory hurdles
- Increasing government & private funding
- Technological advancements
- Limited off-the-shelf delivery systems
- Bioinformatic challenges
SEGMENTATION
- Type
- CRISPR Products
- CRISPR kits & Enzymes
- CRISPR Libraries
- Others
- CRISPR Services
- gRNA Design & Vector Construction
- Cell Line Engineering
- Screening Services
- Others
- Application
- Agriculture
- Biomedical
- Industrial
- Genome Engineering
- Disease Models
- Functional Genomics
- Others
- End User
- Academic Institutes and Research Centers
- Biotechnology Companies
- Contract Research Organizations (CROs)
- Pharmaceutical and Biopharmaceutical Companies
- Others
- North America
- U.S.
- Canada
- Mexico
- Rest of North America
- Europe
- Germany
- U.K.
- France
- Italy
- Spain
- Russia
- The Netherlands
- Belgium
- Turkey
- Rest of Europe
- Asia-Pacific
- China
- India
- Japan
- South Korea
- Singapore
- Malaysia
- Australia
- Thailand
- Philippines
- Rest of Asia-Pacific
- South America
- Brazil
- Argentina
- Chile
- Colombia
- Rest of South America
- Middle East and Africa
- Kingdom of Saudi Arabia
- South Africa
- U.A.E.
- Egypt
- Rest of Middle East and Africa
KEY MARKET PLAYERS
- Thermo Fisher Scientific Inc.
- Merck KGaA
- Agilent Technologies Inc.
- Genscript Biotech Corporation
- CRISPR Therapeutics AG
- Editas Medicine
- Intellia Therapeutics Inc.
- Beam Therapeutics Inc.
- Caribou Biosciences Inc.
- Lonza Group Ltd.
Table OF CONTENTS
- SECTION 1 - INTRODUCTION
- 1.1 Taxonomy
- 1.2 Market Overview
- 1.3 Currency and Limitations
- 1.3.1 Currency
- 1.3.2 Limitations
- 1.4 Key Competitors
- SECTION 2 - RESEARCH METHODOLOGY
- 2.1 Research Approach
- 2.2 Data Collection and Validation
- 2.2.1 Secondary Research
- 2.2.2 Primary Research
- 2.3 Market Assessment
- 2.3.1 Market Size Estimation
- 2.3.2 Bottom-up Approach
- 2.3.3 Top-down Approach
- 2.3.4 Growth Forecast
- 2.4 Market Study Assumptions
- 2.5 Data Sources
- SECTION 3 - EXECUTIVE SUMMARY
- 3.1 Global CRISPR Gene Editing Market, by Type
- 3.2 Global CRISPR Gene Editing Market, by Application
- 3.3 Global CRISPR Gene Editing Market, by End User
- 3.4 Global CRISPR Gene Editing Market, by Geography
- 3.5 Market Position Grid
- SECTION 4 - PREMIUM INSIGHTS
- 4.1 Regulatory Framework
- 4.1.1 Standards
- 4.1.2 Regulatory Landscape
- 4.2 Value Chain Analysis
- 4.3 Supply Chain Analysis
- 4.4 COVID-19 Impact
- 4.5 Russia-Ukraine War Impact
- 4.6 PORTER's Five Force Analysis
- 4.7 PESTLE Analysis
- 4.8 SWOT Analysis
- 4.9 Go to Market Strategy
- 4.10 Opportunity Orbit
- 4.11 Multivariate Modelling
- 4.12 Pricing Analysis
- SECTION 5 - MARKET DYNAMICS
- 5.1 Trends
- 5.1.1 Growing awareness of genetic disorders
- 5.1.2 Expanding applications beyond therapeutics
- 5.1.3 Trend 3
- 5.2 Drivers
- 5.2.1 Rising prevalence of chronic diseases
- 5.2.2 Surging public and private investments
- 5.2.3 Driver 3
- 5.2.4 Driver 4
- 5.3 Restraints
- 5.3.1 High costs associated with CRISPR therapies
- 5.3.2 Ethical concerns and regulatory hurdles
- 5.3.3 Restraint 3
- 5.4 Opportunities
- 5.4.1 Increasing government & private funding
- 5.4.2 Technological advancements
- 5.4.3 Opportunity 3
- 5.4.4 Opportunity 4
- 5.5 Challenges
- 5.5.1 Limited off-the-shelf delivery systems
- 5.5.2 Bioinformatic challenges
- 5.5.3 Challenge 3
- SECTION 6 - GLOBAL CRISPR GENE EDITING MARKET, BY TYPE
- 6.1 Type Summary
- 6.2 Market Attractive Index
- 6.3 Global CRISPR Gene Editing Market, by Type (2019-2032)
- SECTION 7 - GLOBAL CRISPR GENE EDITING MARKET, BY APPLICATION
- 7.1 Application Summary
- 7.2 Market Attractive Index
- 7.3 Global CRISPR Gene Editing Market, by Application (2019-2032)
- SECTION 8 - GLOBAL CRISPR GENE EDITING MARKET, BY END USER
- 8.1 End User Summary
- 8.2 Market Attractive Index
- 8.3 Global CRISPR Gene Editing Market, by End User (2019-2032)
- SECTION 9 - GLOBAL CRISPR GENE EDITING MARKET, BY GEOGRAPHY
- 9.1 Regional Summary
- 9.2 Market Attractive Index
- 9.3 Global CRISPR Gene Editing Market, by Geography (2019-2032)
- SECTION 10 - NORTH AMERICA CRISPR GENE EDITING MARKET
- 10.1 North America Summary
- 10.2 Market Attractive Index
- 10.3 North America CRISPR Gene Editing Market, by Type (2019-2032)
- 10.4 North America CRISPR Gene Editing Market, by Application (2019-2032)
- 10.5 North America CRISPR Gene Editing Market, by End User (2019-2032)
- 10.6 North America CRISPR Gene Editing Market, by Country (2019-2032)
- 10.6.1 U.S.
- 10.6.2 Canada
- 10.6.3 Mexico
- 10.6.4 Rest of North America
- SECTION 11 - EUROPE CRISPR GENE EDITING MARKET
- 11.1 Europe Summary
- 11.2 Market Attractive Index
- 11.3 Europe CRISPR Gene Editing Market, by Type (2019-2032)
- 11.4 Europe CRISPR Gene Editing Market, by Application (2019-2032)
- 11.5 Europe CRISPR Gene Editing Market, by End User (2019-2032)
- 11.6 Europe CRISPR Gene Editing Market, by Country (2019-2032)
- 11.6.1 Germany
- 11.6.2 U.K.
- 11.6.3 France
- 11.6.4 Italy
- 11.6.5 Spain
- 11.6.6 Russia
- 11.6.7 The Netherlands
- 11.6.8 Belgium
- 11.6.9 Turkey
- 11.6.10 Rest of Europe
- SECTION 12 - ASIA-PACIFIC CRISPR GENE EDITING MARKET
- 12.1 Asia-Pacific Summary
- 12.2 Market Attractive Index
- 12.3 Asia-Pacific CRISPR Gene Editing Market, by Type (2019-2032)
- 12.4 Asia-Pacific CRISPR Gene Editing Market, by Application (2019-2032)
- 12.5 Asia-Pacific CRISPR Gene Editing Market, by End User (2019-2032)
- 12.6 Asia-Pacific CRISPR Gene Editing Market, by Country (2019-2032)
- 12.6.1 China
- 12.6.2 India
- 12.6.3 Japan
- 12.6.4 South Korea
- 12.6.5 Singapore
- 12.6.6 Malaysia
- 12.6.7 Australia
- 12.6.8 Thailand
- 12.6.9 Philippines
- 12.6.10 Rest of Asia-Pacific
- SECTION 13 - SOUTH AMERICA CRISPR GENE EDITING MARKET
- 13.1 South America Summary
- 13.2 Market Attractive Index
- 13.3 South America CRISPR Gene Editing Market, by Type (2019-2032)
- 13.4 South America CRISPR Gene Editing Market, by Application (2019-2032)
- 13.5 South America CRISPR Gene Editing Market, by End User (2019-2032)
- 13.6 South America CRISPR Gene Editing Market, by Country (2019-2032)
- 13.6.1 Brazil
- 13.6.2 Argentina
- 13.6.3 Chile
- 13.6.4 Colombia
- 13.6.5 Rest of South America
- SECTION 14 - MIDDLE EAST AND AFRICA CRISPR GENE EDITING MARKET
- 14.1 Middle East and Africa Summary
- 14.2 Market Attractive Index
- 14.3 Middle East and Africa CRISPR Gene Editing Market, by Type (2019-2032)
- 14.4 Middle East and Africa CRISPR Gene Editing Market, by Application (2019-2032)
- 14.5 Middle East and Africa CRISPR Gene Editing Market, by End User (2019-2032)
- 14.6 Middle East and Africa CRISPR Gene Editing Market, by Country (2019-2032)
- 14.6.1 Kingdom of Saudi Arabia
- 14.6.2 South Africa
- 14.6.3 U.A.E.
- 14.6.4 Egypt
- 14.6.5 Rest of Middle East and Africa
- SECTION 15 - COMPANY SHARE ANALYSIS
- 15.1 Global CRISPR Gene Editing Market, Company Share Analysis
- 15.2 North America CRISPR Gene Editing Market, Company Share Analysis
- 15.3 Europe CRISPR Gene Editing Market, Company Share Analysis
- 15.4 Asia-Pacific CRISPR Gene Editing Market, Company Share Analysis
- SECTION 16 - COMPANY PROFILES
- 16.1 Thermo Fisher Scientific Inc.
- 16.1.1 Company Snapshot
- 16.1.2 Financial Overview
- 16.1.3 Product Portfolio
- 16.1.4 Recent Developments
- 16.2 Merck KGaA
- 16.2.1 Company Snapshot
- 16.2.2 Financial Overview
- 16.2.3 Product Portfolio
- 16.2.4 Recent Developments
- 16.3 Agilent Technologies Inc.
- 16.3.1 Company Snapshot
- 16.3.2 Financial Overview
- 16.3.3 Product Portfolio
- 16.3.4 Recent Developments
- 16.4 Genscript Biotech Corporation
- 16.4.1 Company Snapshot
- 16.4.2 Financial Overview
- 16.4.3 Product Portfolio
- 16.4.4 Recent Developments
- 16.5 CRISPR Therapeutics AG
- 16.5.1 Company Snapshot
- 16.5.2 Financial Overview
- 16.5.3 Product Portfolio
- 16.5.4 Recent Developments
- 16.6 Editas Medicine
- 16.6.1 Company Snapshot
- 16.6.2 Financial Overview
- 16.6.3 Product Portfolio
- 16.6.4 Recent Developments
- 16.7 Intellia Therapeutics Inc.
- 16.7.1 Company Snapshot
- 16.7.2 Financial Overview
- 16.7.3 Product Portfolio
- 16.7.4 Recent Developments
- 16.8 Beam Therapeutics Inc.
- 16.8.1 Company Snapshot
- 16.8.2 Financial Overview
- 16.8.3 Product Portfolio
- 16.8.4 Recent Developments
- 16.9 Caribou Biosciences Inc.
- 16.9.1 Company Snapshot
- 16.9.2 Financial Overview
- 16.9.3 Product Portfolio
- 16.9.4 Recent Developments
- 16.10 Lonza Group Ltd.
- 16.10.1 Company Snapshot
- 16.10.2 Financial Overview
- 16.10.3 Product Portfolio
- 16.10.4 Recent Developments
- SECTION 17 - RELATED REPORTS
- SECTION 18 - DISCLAIMER
RESEARCH METHODOLOGY
RESEARCH AND DATA COLLECTION
- Research articles published on Technium
- Science and MDPI
- Research publications by government approved associations and societies
DATA PRE-PROCESSING
The term "data pre-processing" refers to the collection of procedures and methods used to clean, modify, and make ready for analysis the raw data gathered during research and data collection. The completion of this phase is necessary to guarantee that the data are reliable, consistent, and appropriate for statistical analysis and other data-driven tasks. The data pre-processing ensures that the information gathered from research and data collection is comparable and expressed in standard units, by the integration of missing data pointers and algorithmic approaches.
MODELING AND FORECASTING
QUALITY ASSURANCE AND OUTPUT
Quality assurance and output involves the process of validation, adjustments, further publications of key market indicators. Extensive plausibility and consistency tests are performed on derived time series to ensure the high degree of quality of our market analysis. This quality assurance procedure also includes rigorous inspection, validation, and editing by an experienced management team to assure the dependability of the published data.